🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A terrific review on #ADCs in solid tumors led by Salvador Jaime-Casas, MD, working alongside Regina Barragan-Carrillo & mentored by Abhishek Tripathi City of Hope. Salvador is a super hard-working, thoughtful & brilliant med school graduate from #MexicoCity. He's on a roll in his 1st yr with us, being

From envisioning (1st photo), via preparing (2nd photo) to achieving (last photo): Uromigos cup on top of Mount Rainier! Looking forward to next meeting in Nashville Sept 27-28! Brian Rini, MD Tom Powles Sumanta K. Pal, MD, FASCO Tanya Dorff Shilpa Gupta Julie Gralow Rahul Banerjee, MD, FACP Jessica Hawley MD MS

It keeps getting better at the #WorldGU24 World GU Conference 👉 Tanya Dorff provides solid argument for triplet over doublet in many patients with mHSPC #ProstateCancer and her conclusions👇SWOG Cancer Research Network trial on personalized addition of docetaxel in suboptimal PSA response at month 6 coming.

Amazing talk by Elisabeth Heath on the buzz and promise of radiologands and where the field is headed! #WorldGU24 World GU Conference

"BRCA1, BRCA2 & Associated Cancer Risks and Management for Male Patients" Review discusses the underrecognized health implications of inherited cancer-predisposing variants in BRCA1🧬 and BRCA2🧬 (BRCA1/2 PVs) for male carriers, who comprise half of all carriers but are less

Community oncology perspectives from NYCancerSpecialists oncologists on cytoreductive nephrectomy w Uromigos — patients motivated to have surgery. World GU Conference #WorldGU24

Brian Rini, MD pointing out that after ~20 years, we don’t fully know how to use TKIs in mRCC. Intermittent TKI used in real world practice. Provocative supporting data from STAR. Need data of iTKI in prospective obs. studies like ODYSSEY as well. Uromigos World GU Conference #WorldGU24

Fiery discussion on minimal residual disease for #bladdercancer — ctDNA to replace radiology for disease recurrence? Tom Powles says emphatically yes. Brian Rini, MD says maybe complement radiology. We need to await Alliance for Clinical Trials in Oncology #MODERN trial from Matt Galsky Stephanie Berg !

Combo Abi-olaparib better than sequential for BRCA1/2/ATM mutated #prostatecancer. Glad to see #BRCAaway published! Congrats #MahaHussain Neeraj Agarwal, MD, FASCO et al! PCF Science OncoAlert UroToday.com

Our 1st ⁦City of Hope⁩ GU program retreat was an unforgettable day of science and camaraderie. From immunotherapy to theranostics, microbiome to transcriptomics, we are ready to bring hope to all those with GU cancer as our program expands in CA, AZ, Chicago and Atlanta!

Prostate cancer impacts Black men disproportionately vs. men of other backgrounds. Dr. John Carpten says lack of access to the right care is a key disparity Black men face. What are your thoughts? Watch the full recording here: bit.ly/3M5WKAE

Great presentation from Mamta Parikh UC Davis Comprehensive Cancer Cent on mCRPC at #CCCC24! Nice shoutout to Tanya Dorff City of Hope’s CAR-T data in Nature Medicine, among other exciting data in the field. Prostate Cancer Foundation

Tall task given to Tycel Phillips, having to summarize EVERYTHING heme in 15 min at #CCCC24. From #talquetamab in MM (Dr. Amrita Krishnan in NEJM 2022) to #mosunetuzumab in FL (L. Elizabeth Budde, M.D., Ph.D. in The Lancet Oncology 2022) to #venetoclax in AML, he covered a wide range of topics

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

What if #immunotherapy 💉could impact #ProstateCancer as seen w/ #PSA 📉 & #PSMA🩻…but we’ve just been looking 👀 in the wrong place? Stop by @myesmo poster 🖼️ #1614 Sunday in the #ProstateCancer session #ESMO24

Masterful discussion from Petros Grivas -- placing #NIAGARA in context of our #bladdercancer practice -- neoadjuvant and adjuvant OS benefits. Patients are living longer from earlier use of IO agents. Proposes future trial designs. ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors OncoAlert

Dr Apolo Andrea Apolo, M.D. our study chair and bladder cadre leader was center stage to present A031501/AMBASSADOR +DFS and our publication in NEJM This Truly takes a Village! ESMO - Eur. Oncology Alliance for Clinical Trials in Oncology NCICancerTrials Merck SWOG Cancer Research Network ECOG-ACRIN Cancer Research Group #ESMO24 OncoAlert

Fantastic presentation by Tom Powles and discussion by Petros Grivas with full paper out today! #ESMO2024

The honesty, thoughtfulness, and wit of Christopher Sweeney, MBBS Phase 3 trials of Immunotherapy in Prostate Cancer -- A Case Study of "Failed All-Comer Strategy" ⚡️8 negative trials 💰 >$700 million USD 👨‍🦰 7,305 patients #ESMO24 UroToday.com

We presented the 5-year OS update for pts who are cis-ineligible w/met UC treated in EV-103 cohort A/Dose Esc with EV/pembro: 41% of patients are alive at 5 years! (Historical data <5% in a similar pt population). If this holds up in EV302, it is truly a game changer! #ESMO2024